JPH10509038A - 免疫、精製及び検出適用のためのたんぱく質、ペプチド及び複合物の高い水準の発現と容易な精製 - Google Patents
免疫、精製及び検出適用のためのたんぱく質、ペプチド及び複合物の高い水準の発現と容易な精製Info
- Publication number
- JPH10509038A JPH10509038A JP8516180A JP51618096A JPH10509038A JP H10509038 A JPH10509038 A JP H10509038A JP 8516180 A JP8516180 A JP 8516180A JP 51618096 A JP51618096 A JP 51618096A JP H10509038 A JPH10509038 A JP H10509038A
- Authority
- JP
- Japan
- Prior art keywords
- carrier
- protein
- amino acids
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 198
- 102000004169 proteins and genes Human genes 0.000 title claims description 207
- 108090000623 proteins and genes Proteins 0.000 title claims description 207
- 238000000746 purification Methods 0.000 title claims description 24
- 238000001514 detection method Methods 0.000 title claims description 11
- 230000001900 immune effect Effects 0.000 title claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 60
- 230000014509 gene expression Effects 0.000 title description 76
- 150000001413 amino acids Chemical class 0.000 claims abstract description 229
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 183
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 182
- 108091007433 antigens Proteins 0.000 claims abstract description 135
- 102000036639 antigens Human genes 0.000 claims abstract description 135
- 238000000034 method Methods 0.000 claims abstract description 97
- 235000001014 amino acid Nutrition 0.000 claims description 199
- 235000018102 proteins Nutrition 0.000 claims description 191
- 239000003446 ligand Substances 0.000 claims description 152
- 239000000427 antigen Substances 0.000 claims description 144
- 102000014914 Carrier Proteins Human genes 0.000 claims description 140
- 108010078791 Carrier Proteins Proteins 0.000 claims description 140
- 210000004027 cell Anatomy 0.000 claims description 75
- 239000002671 adjuvant Substances 0.000 claims description 67
- 238000004519 manufacturing process Methods 0.000 claims description 64
- 239000000126 substance Substances 0.000 claims description 60
- 239000007924 injection Substances 0.000 claims description 58
- 238000002347 injection Methods 0.000 claims description 58
- 239000013598 vector Substances 0.000 claims description 54
- 230000002209 hydrophobic effect Effects 0.000 claims description 52
- 235000006109 methionine Nutrition 0.000 claims description 51
- 230000027455 binding Effects 0.000 claims description 50
- 229930182817 methionine Natural products 0.000 claims description 50
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 49
- 238000009739 binding Methods 0.000 claims description 47
- 238000012360 testing method Methods 0.000 claims description 43
- 241001465754 Metazoa Species 0.000 claims description 39
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 38
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 37
- 239000004472 Lysine Substances 0.000 claims description 37
- 235000018977 lysine Nutrition 0.000 claims description 37
- 239000013604 expression vector Substances 0.000 claims description 34
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 34
- 239000007787 solid Substances 0.000 claims description 33
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 32
- 235000013922 glutamic acid Nutrition 0.000 claims description 32
- 239000004220 glutamic acid Substances 0.000 claims description 32
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 31
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 31
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 31
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 31
- 235000003704 aspartic acid Nutrition 0.000 claims description 31
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 31
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 30
- 235000018417 cysteine Nutrition 0.000 claims description 30
- 102000004190 Enzymes Human genes 0.000 claims description 29
- 108090000790 Enzymes Proteins 0.000 claims description 29
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 29
- 238000006243 chemical reaction Methods 0.000 claims description 28
- 238000003776 cleavage reaction Methods 0.000 claims description 27
- 238000004458 analytical method Methods 0.000 claims description 26
- 230000007017 scission Effects 0.000 claims description 26
- 230000000890 antigenic effect Effects 0.000 claims description 25
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 25
- 230000002163 immunogen Effects 0.000 claims description 25
- 239000004475 Arginine Substances 0.000 claims description 24
- 235000009697 arginine Nutrition 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 24
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 23
- 239000000872 buffer Substances 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 230000004044 response Effects 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 15
- 230000006872 improvement Effects 0.000 claims description 15
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- -1 aspartyl Chemical group 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 239000000758 substrate Substances 0.000 claims description 10
- 108091005804 Peptidases Proteins 0.000 claims description 9
- 239000004365 Protease Substances 0.000 claims description 9
- 239000007790 solid phase Substances 0.000 claims description 9
- 238000003556 assay Methods 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 8
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 8
- 239000012491 analyte Substances 0.000 claims description 7
- 230000003993 interaction Effects 0.000 claims description 7
- 108091026890 Coding region Proteins 0.000 claims description 6
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 6
- 230000004071 biological effect Effects 0.000 claims description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 5
- 238000003018 immunoassay Methods 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 102000035195 Peptidases Human genes 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 4
- 238000003149 assay kit Methods 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 238000003530 single readout Methods 0.000 claims description 3
- 230000009870 specific binding Effects 0.000 claims description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000009918 complex formation Effects 0.000 claims description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 2
- 230000005661 hydrophobic surface Effects 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 239000013589 supplement Substances 0.000 claims description 2
- 230000007613 environmental effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 75
- 230000016784 immunoglobulin production Effects 0.000 abstract description 6
- 229940024606 amino acid Drugs 0.000 description 152
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 39
- 239000000523 sample Substances 0.000 description 37
- 230000004927 fusion Effects 0.000 description 35
- 239000013612 plasmid Substances 0.000 description 35
- 108020004414 DNA Proteins 0.000 description 34
- 230000008901 benefit Effects 0.000 description 34
- 241000700159 Rattus Species 0.000 description 32
- 230000003053 immunization Effects 0.000 description 32
- 108091034117 Oligonucleotide Proteins 0.000 description 30
- 239000003153 chemical reaction reagent Substances 0.000 description 30
- 239000000047 product Substances 0.000 description 30
- 101710123496 Spindolin Proteins 0.000 description 29
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 29
- 230000015572 biosynthetic process Effects 0.000 description 26
- 210000000987 immune system Anatomy 0.000 description 26
- 238000002649 immunization Methods 0.000 description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 230000028993 immune response Effects 0.000 description 19
- 238000010561 standard procedure Methods 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 229960000583 acetic acid Drugs 0.000 description 14
- 210000002865 immune cell Anatomy 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 241000894007 species Species 0.000 description 14
- 239000002585 base Substances 0.000 description 13
- 238000010367 cloning Methods 0.000 description 13
- 238000013461 design Methods 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 12
- 230000005875 antibody response Effects 0.000 description 12
- 239000011347 resin Substances 0.000 description 12
- 229920005989 resin Polymers 0.000 description 12
- 210000003000 inclusion body Anatomy 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- 230000014616 translation Effects 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 10
- 241000287828 Gallus gallus Species 0.000 description 10
- 235000013330 chicken meat Nutrition 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 241001529936 Murinae Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 239000000539 dimer Substances 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical group C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 7
- 239000003599 detergent Substances 0.000 description 7
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 6
- 108020005038 Terminator Codon Proteins 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 238000004007 reversed phase HPLC Methods 0.000 description 6
- 102000004533 Endonucleases Human genes 0.000 description 5
- 108010042407 Endonucleases Proteins 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 5
- 150000005829 chemical entities Chemical class 0.000 description 5
- 229960003964 deoxycholic acid Drugs 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 125000001360 methionine group Chemical class N[C@@H](CCSC)C(=O)* 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 101710137500 T7 RNA polymerase Proteins 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000010265 fast atom bombardment Methods 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 241000701867 Enterobacteria phage T7 Species 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 101150052859 Slc9a1 gene Proteins 0.000 description 3
- 240000001949 Taraxacum officinale Species 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000002297 mitogenic effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 150000002972 pentoses Chemical group 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000004850 protein–protein interaction Effects 0.000 description 3
- 230000009919 sequestration Effects 0.000 description 3
- 238000010583 slow cooling Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- 101100083742 Caenorhabditis elegans pmk-1 gene Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 241000245665 Taraxacum Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical group 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000011091 antibody purification Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 108010093581 aspartyl-proline Proteins 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 229940009976 deoxycholate Drugs 0.000 description 2
- 238000012938 design process Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- FRTGEIHSCHXMTI-UHFFFAOYSA-N dimethyl octanediimidate Chemical compound COC(=N)CCCCCCC(=N)OC FRTGEIHSCHXMTI-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 239000012070 reactive reagent Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- OIXLLKLZKCBCPS-RZVRUWJTSA-N (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CCCNC(N)=N OIXLLKLZKCBCPS-RZVRUWJTSA-N 0.000 description 1
- YVOOPGWEIRIUOX-UHFFFAOYSA-N 2-azanyl-3-sulfanyl-propanoic acid Chemical compound SCC(N)C(O)=O.SCC(N)C(O)=O YVOOPGWEIRIUOX-UHFFFAOYSA-N 0.000 description 1
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- QEYONPKSDTUPAX-UHFFFAOYSA-N 4-bromo-2-chloro-6-fluorophenol Chemical compound OC1=C(F)C=C(Br)C=C1Cl QEYONPKSDTUPAX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- UKGGPJNBONZZCM-WDSKDSINSA-N Asp-Pro Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O UKGGPJNBONZZCM-WDSKDSINSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000168022 Elaphurus davidianus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- JPHYJQHPILOKHC-ACZMJKKPSA-N Glu-Asp-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O JPHYJQHPILOKHC-ACZMJKKPSA-N 0.000 description 1
- GYCPQVFKCPPRQB-GUBZILKMSA-N Glu-Gln-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)N GYCPQVFKCPPRQB-GUBZILKMSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000617808 Homo sapiens Synphilin-1 Proteins 0.000 description 1
- 206010021432 Immunisation reaction Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 108010030544 Peptidyl-Lys metalloendopeptidase Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- YHUBAXGAAYULJY-ULQDDVLXSA-N Pro-Tyr-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O YHUBAXGAAYULJY-ULQDDVLXSA-N 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102100021997 Synphilin-1 Human genes 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013531 gin Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 230000033687 granuloma formation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 108091006058 immobilized fusion proteins Proteins 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000001452 natriuretic effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 210000002729 polyribosome Anatomy 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 102000012498 secondary active transmembrane transporter activity proteins Human genes 0.000 description 1
- 108040003878 secondary active transmembrane transporter activity proteins Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10211—Podoviridae
- C12N2795/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 天然には存在しない疎水性で殆ど不溶のアミノ酸配列からなる融合たん ぱく質キャリアーセグメント。 2. 該アミノ酸配列は実質的に抗原性が無い請求項1のキャリアーセグメン ト。 3. 該アミノ酸配列は以下の負若しくは正電荷を持つ側鎖のアミノ酸:アル ギニン、リシン、アスパルチック酸、グルタミック酸;又は無電荷の側鎖の以下 のアミノ酸:システイン、トリプトファン及びメチオニン(アミノ末端部位にあ るメチオニンを除く)とからなる群から選択された少なくとも2つのアミノ酸を 欠いている請求項1のキャリアーセグメント。 4. 該キャリアーセグメントはおよそ5%より多くない以下のアミノ酸:ア ルギニン、リシン、アスパルチック酸、グルタミック酸、システイン、トリプト ファン及びメチオニンからなる請求項1のキャリアーセグメント。 5. 少なくとも約65アミノ酸長の長さを有する請求項1のキャリアーセグ メント。 6. 図1〔SEQ.ID.1〕中に示された配列からなる請求項1のキャリ アーセグメント。 7. 図3〔SEQ.ID.2〕中に示され配列からなる請求項1のキャリア ーセグメント。 8. 請求項1のアミノ酸配列からなるベクター。 9. 請求項9のベクターを伴い転換されたホスト細胞。 10. 以下の負若しくは正電荷を持つ側鎖のアミノ酸:アルギニン、リシン 、アスパルチック酸、グルタミック酸;又は無電荷の側鎖の以下のアミノ酸:シ ステイン、トリプトファン及びメチオニン(アミノ末端部位にあるメチオニンを 除く)とからなる群から選択された少なくとも2つのアミノ酸を欠いている、少 なくとも約65アミノ酸長の長さを有する天然には存在しない、疎水性の、殆ど 不溶のアミノ酸配列からなる実質的に抗原性の無い融合たんぱく質キャリアーセ グメント。 11. 図1〔SEQ.ID.1〕中に示された配列からなる請求項10のキ ャリアーセグメント。 12. 図3〔SEQ.ID.2〕中に示された配列からなる請求項10のキ ャリアーセグメント。 13. およそ5%より多くない以下のアミノ酸:アルギニン、リシン、アス パルチック酸、グルタミック酸、システイン、トリプトファン及びメチオニンか らなる少なくとも約65アミノ酸長の長さを有する天然には存在しない、疎水性 の、殆ど不溶のアミノ酸配列からなる実質的に抗原性の無い融合たんぱく質キャ リアーセグメント。 14. a.少なくとも約65アミノ酸長であり、そして以下の負若しくは正 電荷を持つ側鎖のアミノ酸:アルギニン、リシン、アスパルチック酸、グルタミ ック酸;又は無電荷の側鎖の以下のアミノ酸:システイン、トリプトファン及び メチオニン(アミノ末端部位にあるメチオニンを除く)とからなる群から選択さ れた少なくとも2つのアミノ酸を欠いている第一のアミノ酸配列と; b.該第一のアミノ酸配列に融合された配位子と: からなるキャリアーたんぱく質複合体。 15. 融合たんぱく質は第二のアミノ酸配列の生物学的活性を示して該配位 子は生物学的に活性なアミノ酸配列である請求項14のキャリアーたんぱく質複 合体。 16. 該配位子は原核性の、若しくは真核性の、若しくは環境由来の源から 派生したペプチドである請求項15のキャリアーたんぱく質複合体。 17. 該配位子はハプテンである請求項14のキャリアーたんぱく質複合体 。 18. 該配位子はエピトープである請求項14のキャリアーた んぱく質複合体。 19. 該配位子は免疫学的結合活性を持つ請求項14のキャリアーたんぱく 質複合体。 20. 請求項14記載のキャリアーたんぱく質複合体からなる、ホスト動物 への注入のための抗原 21. 図1〔SEQ.ID.1〕中に示されたアミノ酸配列。 22. 図3〔SEQ.ID.2〕中に示されたアミノ酸配列。 23. 図1〔SEQ.ID.1〕中に示されたアミノ酸配列と該アミノ酸配 列に融合された配位子からなる天然には存在しないキャリアーたんぱく質複合体 。 24. 該アミノ酸はカルボキシ末端でペプチドセグメントのN−末端に結合 される請求項23のキャリアーたんぱく質複合体。 25. 以下の負若しくは正電荷を持つ側鎖のアミノ酸:アルギニン、リシン 、アスパルチック酸、グルタミック酸;又は無電荷の側鎖の以下のアミノ酸:シ ステイン、トリプトファン及びメチオニン(アミノ末端部にあるメチオニンを除 く)とからなる群から選択された少なくとも2つのアミノ酸を欠いている天然に は存在しない疎水で殆ど不溶のアミノ酸配列と配位子によりコード化された粒子 形状融合たんぱく質を発現する、抗原のためのコード化配列を持つ単一の読み出 しフレーム中のアミノ酸配列からなる発現ベクター。 26. 請求項の該ベクターで転換されたホスト細胞。 27. 天然には存在しない、疎水で、殆ど不溶のアミノ酸配列からなるホス ト動物に免疫原を投与するための補助薬。 28. 該アミノ酸配列は実質的に抗原性が無い請求項27の補助薬。 29. 該アミノ酸配列は以下の負若しくは正電荷を持つ側鎖のアミノ酸:ア ルギニン、リシン、アスパルチック酸、グルタミック酸;又は無電荷の側鎖の以 下のアミノ酸:システイン、トリプトファン及びメチオニン(アミノ末端部にあ るメチオニンを除く)と からなる群から選択された少なくとも2つのアミノ酸を欠いている請求項27の 補助薬。 30. 少なくとも約65アミノ酸長の長さを持つ請求項27の補助薬。 31. 図1〔SEQ.ID.1〕中に示された配列からなる請求項27の補 助薬。 32. 図3〔SEQ.ID.2〕中に示された配列からなる請求項27の補 助薬。 33. a. キャリアーたんぱく質複合体を形成するために配位子へ天然に は存在しない、疎水で、殆ど不溶のアミノ酸配列からなる融合たんぱく質キャリ アーセグメントを融合する段階と、 b. 抗原を生体内又は生体外の手段で送り込む段階と; c. 配位子への抗体を生成する段階と; からなる、配位子への抗体を生産する製造方法。 34. ホスト動物中に融合たんぱく質を注入する生体内工程により該抗原を 送り込むことからなる請求項33に製造方法。 35. 生体外で培養された細胞でキャリアーたんぱく質複合体を培養する生 体外工程より該抗原を送り込むことよりなる請求項33に製造方法。 36. 請求項33の製造方法に従い製造されたたんぱく質への抗体。 37. (a)少なくとも一のキャリアーたんぱく質合成物が捕獲剤として固 体相へ付着され、抗原/抗体錯体の形成に適当な時間と条件のもとで試験試料と 接触され、そして(b)発せられた信号は試験試料中の反−分析抗体の存在を指 示するものである、信号発生化合物と分析物のための特定の結合部分からなる指 示薬が、反応が起きるのに十分な時間の間に該錯体と接触し、改善点は、天然に は存在しない疎水で殆ど不溶のアミノ酸配列からなる融合たんぱく質キャリアー セグメントを捕獲剤として固体相に付着させることからなる、試験試料中の反抗 原抗体の濃度を決めるための分析方法にある。 38. キャリアーたんぱく質複合体のペプチド構造により限定されるエピト ープで該抗体を同定することよりなる請求項37分析方法。 39. a. 以下の負若しくは正電荷を持つ側鎖のアミノ酸:アルギニン、 リシン、アスパルチック酸、グルタミック酸;又は無電荷の側鎖の以下のアミノ 酸:システイン、トリプトファン及びメチオニン(アミノ末端部にあるメチオニ ンを除く)とからなる群から選択された少なくとも2つのアミノ酸を欠き、少な くとも約65アミノ酸長の長さを持ち、天然には存在しない、疎水で、殆ど不溶 のアミノ酸配列を含む実質的に抗原性の無い融合たんぱく質キャリアーセグメン トからなる免疫原を調製する段階と; b. ホスト脊椎動物に該キャリアーたんぱく質複合体を投与する段 階と: からなる、ホスト脊椎動物に免疫原を接種するための方法。 40. a. 図1(SEQ.ID.1)中に示されたアミノ酸配列と該アミ ノ酸配列に融合された配位子からなる天然には存在しないキャリアーたんぱく質 複合体からなる免疫原を形成する段階と; b. ホスト脊椎動物に該キャリアーたんぱく質複合体を投与する段 階と: からなるホスト脊椎動物に免疫原を接種するための方法。 41. a. 以下の負若しくは正電荷を持つ側鎖のアミノ酸:アルギニン、 リシン、アスパルチック酸、グルタミック酸;又は無電荷の側鎖の後続アミノ酸 :システイン、トリプトファン及びメチオニン(アミノ末端部にあるメチオニン を除く)とからなる群から選択された少なくとも2つの追従アミノ酸を欠いてお り、少なくとも約65アミノ酸長の長さを持ち、天然には存在しない疎水で殆ど 不溶のアミノ酸配列を含む実質的に抗原性の無い融合たんぱく質キャリアーセグ メントからなる免疫原を形成する段階と; b. 抗体/複合体錯体を形成するためにキャリアーたんぱく質複合 体に抗体物質を結合する束縛条件下でキャリアーたんぱく質複合体と抗体物質を 培養する段階と; c. 抗体/複合体錯体を分離する段階と; d. 抗体/複合体錯体から抗体を解離する段階と; e. 抗体/複合体錯体から抗体を分離する段階と: からなる抗体物質溜めから抗体を免疫精製する方法。 42. 請求項41の製造方法に従う起原免疫原のサブセットに対し特異的な 抗体の精製をするために、その配位子が該起原免疫原中に含まれる一部であるキ ャリアーたんぱく質複合体の使用。 43. a. 以下の負若しくは正電荷を持つ側鎖のアミノ酸:アルギニン、 リシン、アスパルチック酸、グルタミック酸;又は無電荷の側鎖の以下のアミノ 酸:システイン、トリプトファン及びメチオニン(アミノ末端部にあるメチオニ ンを除く)とからなる群から選択された少なくとも2つのアミノ酸を欠き、天然 には存在しない疎水で殆ど不溶のアミノ酸配列を含む融合たんぱく質キャリアー セグメントからなる融合たんぱく質を、融合たんぱく質上のペプチ ド結合が解裂される条件下で培養する段階と; b. 望みのペプチドを分離する段階と: からなる、ペプチド製造方法。 44. 該融合たんぱく質はキャリアーセグメント(アミノ末端部にあるメチ オニンを除く)中には見出されない解裂部位を含む請求項43の製造方法。 45. 該解裂部位は以下の負若しくは正電荷を持つ側鎖のアミノ酸:アルギ ニン、リシン、アスパルチック酸、グルタミック酸;又は無電荷の側鎖の以下の アミノ酸:システイン、トリプトファン及びメチオニン(アミノ末端部にあるメ チオニンを除く)とからなる群から選択されたアミノ酸と該キャリアーセグメン ト中には含まれない知られたプロテアーゼからの他の知られた解裂部位を含む請 求項43の製造方法。 46. 該キャリアーセグメントを沈殿することにより解裂後に該ペプチドか ら該キャリアーセグメントを分離することからなる請求項43の製造方法。 47. 疎水性の表面へ該キャリアーセグメントを吸収することにより解裂後 に該ペプチドから該キャリアーセグメントを分離することからなる請求項43の 製造方法。 48. 天然には存在しない疎水で殆ど不溶のアミノ酸配列を含む融合たんぱ く質キャリアーセグメントとそこで融合たんぱく質が単離されて競争阻害性の基 体として用いられる、プロテアーゼのための解裂部位とからなる融合たんぱく質 からなるプロテアーゼ阻害剤。 49. 該アミノ酸配列は以下の負若しくは正電荷を持つ側鎖のアミノ酸:ア ルギニン、リシン、アスパルチック酸、グルタミック酸;又は無電荷の側鎖の以 下のアミノ酸:システイン、トリプトファン及びメチオニン(アミノ末端部にあ るメチオニンを除く)とからなる群から選択された少なくとも2つのアミノ酸を 欠く請求項 48のプロテアーゼ阻害剤。 50. a. 第一のアミノ酸配列は少なくとも約65アミノ酸長であり、以 下の負若しくは正電荷を持つ側鎖のアミノ酸:アルギニン、リシン、アスパルチ ック酸、グルタミック酸;又は無電荷の側鎖の以下のアミノ酸:システイン、ト リプトファン及びメチオニン(アミノ末端部にあるメチオニンを除く)とからな る群から選択された少なくとも2つのアミノ酸を欠く、第一のアミノ酸キャリア ー配列と; b. 該第一のアミノ酸キャリアー配列に融合した配位子と: からなる、その上でキャリアーたんぱく質合成物を吸収する固体支持物。 51. 診断分析における使用のための請求項50の固体支持物。 52. 該配位子は問題のたんぱく質に選択的に結合するように適合される、 たんぱく質の結合性精製における使用のための請求項50の固体支持物。 53. 該配位子は特定の細胞型又は特定の生育段階にある細胞に選択的に結 合するように適合される、たんぱく質の結合性分離における使用のための請求項 50の固体支持物。 54. 該配位子は第二のたんぱく質の選択された領域と相互作用するたんぱ く質の領域を含む、選択されたたんぱく質の間の相互作用の研究における使用の ための請求項50の固体支持物。 55. (a)酵素が活動できる配位子を含む少なくとも一のキャリアーたん ぱく質複合体が固体相に付着されて、酵素が基体上で活動するのに適当な時間と 条件のもとで試験試料に接触され、 (b)発せられた信号が試験試料中の酵素の存在を示し、固定化基体の酵素に触 媒された改良に応答して信号の変化を発生することの 可能な信号発生剤が、反応が十分起きる時間の間に錯体に接触され、改善点は、 捕獲剤として固体相へ、天然には存在しない疎水で殆ど不溶のアミノ酸配列を含 む組み換え融合たんぱく質キャリアーセグメントを付着させることからなる試験 試料中の酵素の濃度を決める分析方法にある。 56. 反−抗原抗体のための少なくとも一のたんぱく質の特質を含む容器を 含み、改善点は反−抗原抗体に対し特異的である天然には存在しない疎水で殆ど 不溶のアミノ酸配列を含む容器からなる試験試料中の反−抗原抗体の存在を検出 する使用のための試験キット。 57. a. 望みの抗原と特異的に反応する請求項33の方法により製造さ れた一又はそれ以上の抗体をそこに結合した固体支持物と; b. 結合されないたんぱく質を除く緩衝剤と; c. 結合された分析試料の検出のための溶液と; d. 使用のための指示書と; を分離された容器に含む、特定の抗原を検出するための免疫分析キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/338,382 US6069230A (en) | 1994-11-10 | 1994-11-10 | High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications |
US08/338,382 | 1994-11-10 | ||
PCT/US1995/014518 WO1996015249A1 (en) | 1994-11-10 | 1995-11-13 | High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10509038A true JPH10509038A (ja) | 1998-09-08 |
Family
ID=23324602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8516180A Ceased JPH10509038A (ja) | 1994-11-10 | 1995-11-13 | 免疫、精製及び検出適用のためのたんぱく質、ペプチド及び複合物の高い水準の発現と容易な精製 |
Country Status (6)
Country | Link |
---|---|
US (2) | US6069230A (ja) |
EP (1) | EP0791068A1 (ja) |
JP (1) | JPH10509038A (ja) |
AU (1) | AU707030B2 (ja) |
CA (1) | CA2204914A1 (ja) |
WO (1) | WO1996015249A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020515629A (ja) * | 2017-04-04 | 2020-05-28 | アヴィディア テクノロジーズ, インコーポレイテッド | 免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6764689B1 (en) * | 1994-11-10 | 2004-07-20 | Promega Corporation | High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications |
TR199802421T2 (xx) * | 1996-05-24 | 1999-02-22 | Biogen , Inc. | Doku yenilenmesini d�zenleyen maddeler. |
US6297361B1 (en) * | 1997-01-06 | 2001-10-02 | Promega Corporation | Use of histidine decarboxylase immunoreactivity to detect human cancer |
WO2001002588A2 (en) * | 1999-07-02 | 2001-01-11 | Morphosys Ag | Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests |
US7846746B2 (en) * | 2001-04-10 | 2010-12-07 | Children's Medical Center Corporation | Methods of analysis and labeling of protein-protein interactions |
DK1436331T3 (da) * | 2001-10-17 | 2007-10-22 | Council Scient Ind Res | Fremgangsmåde til fremstillingen af æggeblommeantistoffer imod organochlorpesticider |
EP1532262B1 (en) * | 2002-05-24 | 2013-07-10 | Medtronic, Inc. | Peptide amidation process |
JP2005532405A (ja) * | 2002-07-10 | 2005-10-27 | アクゾ・ノベル・エヌ・ベー | 融合タンパク質とサポニンアジュバントとを含む免疫原性組成物 |
WO2004056865A2 (en) * | 2002-12-20 | 2004-07-08 | Enkam Pharmaceuticals A/S | Method of modulation of interaction between receptor and ligand |
DE10306331A1 (de) * | 2003-02-11 | 2004-09-02 | Varicula Life Science Ag | Verfahren zur Herstellung von BK-RiV-spezifischen Präparaten und deren Anwendung in der Human- und Veterinärmedizin |
FR2862661B1 (fr) * | 2003-11-26 | 2007-10-05 | Agronomique Inst Nat Rech | Utilisation de la l-isoaspartyl methyltransferase comme marqueur de longevite des semences. |
US8647857B2 (en) * | 2008-04-30 | 2014-02-11 | Gradalis, Inc. | Processes for the digestion of colanic acid |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH024179A (ja) * | 1988-06-20 | 1990-01-09 | Daikin Ind Ltd | 冷却装置 |
US5103459A (en) * | 1990-06-25 | 1992-04-07 | Qualcomm Incorporated | System and method for generating signal waveforms in a cdma cellular telephone system |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4512922A (en) * | 1982-12-22 | 1985-04-23 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4952496A (en) * | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
US4743679A (en) * | 1986-02-24 | 1988-05-10 | Creative Biomolecules, Inc. | Process for producing human epidermal growth factor and analogs thereof |
US5041385A (en) * | 1986-11-01 | 1991-08-20 | Oxford Gene Systems Limited | Vector expressing fusion proteins and particles |
US5215896A (en) * | 1987-03-20 | 1993-06-01 | Creative Biomolecules, Inc. | Leader sequences for the production of recombinant proteins |
US5043158A (en) * | 1987-08-21 | 1991-08-27 | Chembiomed, Ltd. | Immunogenic compositions containing ordered carriers |
US5322769A (en) * | 1988-03-11 | 1994-06-21 | Abbott Laboratories | Methods for using CKS fusion proteins |
US5202239A (en) * | 1990-08-07 | 1993-04-13 | Scios Nova Inc. | Expression of recombinant polypeptides with improved purification |
-
1994
- 1994-11-10 US US08/338,382 patent/US6069230A/en not_active Expired - Fee Related
-
1995
- 1995-11-13 JP JP8516180A patent/JPH10509038A/ja not_active Ceased
- 1995-11-13 EP EP95943330A patent/EP0791068A1/en not_active Withdrawn
- 1995-11-13 WO PCT/US1995/014518 patent/WO1996015249A1/en active Application Filing
- 1995-11-13 AU AU44623/96A patent/AU707030B2/en not_active Ceased
- 1995-11-13 CA CA002204914A patent/CA2204914A1/en not_active Abandoned
-
1998
- 1998-10-16 US US09/174,060 patent/US5989554A/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH024179A (ja) * | 1988-06-20 | 1990-01-09 | Daikin Ind Ltd | 冷却装置 |
US5103459A (en) * | 1990-06-25 | 1992-04-07 | Qualcomm Incorporated | System and method for generating signal waveforms in a cdma cellular telephone system |
US5103459B1 (en) * | 1990-06-25 | 1999-07-06 | Qualcomm Inc | System and method for generating signal waveforms in a cdma cellular telephone system |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020515629A (ja) * | 2017-04-04 | 2020-05-28 | アヴィディア テクノロジーズ, インコーポレイテッド | 免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用 |
Also Published As
Publication number | Publication date |
---|---|
AU4462396A (en) | 1996-06-06 |
CA2204914A1 (en) | 1996-05-23 |
AU707030B2 (en) | 1999-07-01 |
EP0791068A1 (en) | 1997-08-27 |
US5989554A (en) | 1999-11-23 |
US6069230A (en) | 2000-05-30 |
WO1996015249A1 (en) | 1996-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2144424T5 (es) | Vacuna que comprende parte de la region constante de ige para el tratamiento de reacciones alergicas inducidas por ige. | |
US5328985A (en) | Recombinant streptavidin-protein chimeras useful for conjugation of molecules in the immune system | |
CN100385002C (zh) | 重组融合蛋白的二聚体、三聚体、四聚体或五聚体的二聚物或寡聚物 | |
US5965709A (en) | IgE antagonists | |
SK11295A3 (en) | Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them | |
JPH10509038A (ja) | 免疫、精製及び検出適用のためのたんぱく質、ペプチド及び複合物の高い水準の発現と容易な精製 | |
EP0759941A1 (en) | Heterodimer polypeptide immunogen carrier composition and method | |
KR19990036440A (ko) | 알러젠-xcd32융합 단백질 | |
US20070014809A1 (en) | B Cell Activation and Polypeptides Having CD14 Activity | |
US5763284A (en) | Methods for peptide synthesis and purification | |
JPH03155787A (ja) | Ebzd蛋白質発現系 | |
US5514776A (en) | Peptides representing antigenic epitopes of dog IgE present on B cell but not basophil surface | |
CN113912716B (zh) | 针对α-突触核蛋白抗原的抗体及其应用 | |
Burt et al. | Use of synthetic peptides in the production and characterization of antibodies directed against predetermined specificities in rat immunoglobulin E | |
US6764689B1 (en) | High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications | |
CN114163504A (zh) | SARS-CoV-2 S蛋白RBD区中和表位肽及其应用 | |
WO1994020533A1 (en) | PEPTIDES REPRESENTING ANTIGENIC EPITOPES OF IgE PRESENT ON B CELL BUT NOT BASOPHIL SURFACE | |
JPH03504729A (ja) | マルトースに対して親和性のある物質(MalE)と、HIVウイルスに対する中和特性を有するCD4タンパク質フラグメントとの融合によって生じた融合CD4ポリペプチド | |
Shen et al. | Construction and expression of a new fusion protein, thymosin α 1–cBLyS, E. coli | |
CN114716567A (zh) | 一种嵌合体抗原和抗金环蛇蛇毒制剂的制备方法及其应用 | |
KR101633791B1 (ko) | 수크라아제-이소말타아제에 대한 항체의 제조 방법 | |
WO2022096738A1 (en) | Novel type ii collagen binding proteins | |
JP2002539818A (ja) | イヌのアレルギーを治療するための特異的結合蛋白 | |
JPH06125784A (ja) | モノクローナル抗体,ハイブリドーマ,その製造法および用途 | |
Mahassni et al. | Production of metal ion-dependent monoclonal antibodies against peptides in bovine prothrombin fragment 1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070206 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070507 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080401 |
|
LAPS | Cancellation because of no payment of annual fees | ||
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080826 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081014 |